Kesimpta market seen topping $14 billion by 2030

The Business Research Company projects the global Kesimpta market will surpass $14 billion in 2030, driven by rising multiple sclerosis diagnoses, self-administered biologic therapies and long-term disease control demand. North America and the U.S. are expected to lead the market, while adult patients account for the largest share.

Why it matters: - The forecast points to fast growth for Kesimpta in the multiple sclerosis treatment market through 2030. - The drug is expected to reach more than $14 billion in global sales by 2030. - Kesimpta is projected to represent about 6% of the $225 billion central nervous system drugs market and nearly 1% of the $2.496 trillion pharmaceuticals market.

What happened: - The Business Research Company published its "Kesimpta Market Report 2026 – Market Size, Trends, And Global Forecast 2026-2035." - The report estimates the Kesimpta market will grow at a 27% CAGR leading up to 2030. - North America is projected to be the largest region in 2030, with a market value of $8.2 billion. - The U.S. is projected to be the largest country in 2030, with a market value of $7.5 billion. - Adult patients are expected to be the largest patient group, accounting for 84% of the market, or about $12 billion, in 2030.

The details: - North America is forecast to grow from $3.2 billion in 2025 to $8.2 billion in 2030, a 21% CAGR. - The U.S. market is expected to rise from $2.9 billion in 2025 to $7.5 billion in 2030, a 20% CAGR. - The report links North American growth to higher multiple sclerosis prevalence, broader use of self-administered biologics, earlier diagnosis, specialty neurology networks and higher healthcare spending. - The U.S. outlook reflects rising diagnosis rates of relapsing multiple sclerosis, physician preference for targeted B-cell therapies, insurance coverage for specialty biologics and demand for at-home treatment. - The adult-patient segment is supported by the prevalence of multiple sclerosis among adults, growing treatment uptake among working-age patients and expanded access to specialty neurological care. - The market is also segmented by indication into treatment of rhabdomyosarcoma, clinically isolated syndrome and active secondary progressive multiple sclerosis. - Other segments include injectable formulation, pre-filled syringes or autoinjectors, direct sales, wholesalers and distributors, retail pharmacies, online pharmacies, hospitals, specialty pharmacies, home healthcare providers and neurology clinics. - The report says the pediatric, adult and geriatric segments together could add more than $9.2 billion in market value by 2030. - The report projects the pediatric segment will grow by $0.2 billion, the adult segment by $8 billion and the geriatric segment by $1 billion from 2025 to 2030. - The company also says its 2026 reports now include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, and key technologies and future trend analysis. - A free sample of the report is available here. - The full report is available here.

Between the lines: - The forecast reflects a broader shift toward earlier diagnosis and long-term management of chronic neurological disease. - Home-based and self-administered treatment options are becoming a central growth theme because they reduce hospital dependence and may improve adherence. - Strong clinical efficacy remains a selling point as providers look for therapies that reduce relapse activity and slow disability progression. - The report frames its estimates as market research projections, not guaranteed outcomes.

What's next: - The market is expected to keep expanding toward 2030 if diagnosis rates, insurance access and adoption of at-home biologics continue to improve. - Growth will likely remain concentrated in adult patients, North America and the U.S. - The report points to pediatric and geriatric segments as additional opportunities, though they remain far smaller than the adult market.